Background: In recent years, the incidence of pediatric hepatoblastoma has increased significantly. The aims of our study were to analyze the incidence trends, identify independent risk factors affecting the prognosis, and create a nomogram based on these risk factors to guide clinical treatment.
Methods: The Clinicopathological data from children diagnosed with hepatoblastoma between 2000 and 2018 were extracted from the SEER database to analyze the incidence trends. Independent risk factors were screened by COX, LASSO and BSR to construct a nomogram. X-tile software was used to determine the optimal threshold and to identify high-risk and low-risk groups. Kaplan-Meier method was used to draw the subgroup survival curve.
Results: A total of 810 children with hepatoblastoma were included in this study. The APC was 1.6 % (95 % confidence interval [CI] -0.6 %-3.9 %, P < 0.05). Race, age, tumor size, type of surgery, and chemotherapy were independent risk factors. The time-varying AUC (>0.7) and time-varying c index (>0.7) indicate that nomogram has good discriminative ability. The calibration graphs show that the predicted results of the modal graphs are in good agreement with the actual observed results in the training and validation queues. In addition, DCA demonstrated the value of nomogram in clinical application and differentiation.
Conclusion: The incidence of hepatoblastoma in children has increased. We construct a nomogram to predict prognosis and guide treatment. The combination of surgery and chemotherapy is highly likely to extend survival and improve patient outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejso.2025.109694 | DOI Listing |
Global Spine J
March 2025
Combined Neurosurgical and Orthopaedic Spine Program, University of British Columbia, Vancouver, BC, Canada.
Study DesignNarrative Review.ObjectivesTo summarize the work of the AO Spine Knowledge Forum Tumor, specifically studies from the Epidemiology, Process and Outcomes in Spine Oncology (EPOSO) study.MethodsA narrative review of all published manuscripts from the EPOSO study was undertaken.
View Article and Find Full Text PDFAnn Oncol
February 2025
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Electronic address:
Background: We predicted the number of cancer deaths and rates for 2025 in the European Union (EU), its five most populous countries, and the UK, focusing on breast cancer.
Materials And Methods: We derived population data and death certificates for all cancers and major sites for the EU, France, Germany, Italy, Poland, Spain, and the UK since 1970, from the World Health Organization and United Nations databases. Estimates for 2025 were computed by linear regression on recent trends identified through Poisson joinpoint regression, considering the slope of the most recent trend segment.
J Am Coll Cardiol
March 2025
National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed chronic disease associated with progressive heart failure that results in impaired quality of life, repeated hospitalizations, and premature death. Acoramidis is a selective, oral transthyretin stabilizer recently approved by the U.S.
View Article and Find Full Text PDFEnviron Health Prev Med
March 2025
Department of Biostatistics, School of Public Health, Harbin Medical University.
Background: There is growing evidence that the occurrence and severity of respiratory diseases in children are related to the concentration of air pollutants. Nonetheless, evidence regarding the association between short-term exposure to air pollution and outpatient visits for respiratory diseases in children remains limited. Outpatients cover a wide range of disease severity, including both severe and mild cases, some of which may need to be transferred to inpatient treatment.
View Article and Find Full Text PDFOccup Environ Med
March 2025
Research Directorate, Veterans Affairs Canada, Charlottetown, Prince Edward Island, Canada
Objectives: To describe rates of overall and type-specific primary cancers in Canadian Armed Forces (CAF) personnel and Veterans with a first enrolment in the CAF between 1976 and 2016, with comparisons to the Canadian general population (CGP).
Methods: This retrospective cohort study linked CAF administrative data to national cancer registries. Primary cancer diagnoses were ascertained from 1976 to 2017.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!